Gene polymorphisms of the NOD-2/CARD-15 gene and the risk of gastric cancer in Germany

Anticancer Research

Volumn 28, Issue 2 A, 2008, Pages 757-762

  Wex, Thomas ^a   Ebert, Matthias P A ^b   Kropf, Siegfried ^a   Dierkes, Jutta ^a   Schüttler, Katrin ^a   Röcken, Christoph ^c   Höcker, Michael ^c   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Gastric cancer; NOD 2; Polymorphisms; Stomach

Indexed keywords

AGED; ARTICLE; CANCER RISK; CARD 15 GENE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE; GENE MUTATION; GENOTYPE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NOD 2 GENE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; STOMACH CARCINOGENESIS;

AGED; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HUMANS; MALE; MIDDLE AGED; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; STOMACH NEOPLASMS;

EID: 42549124086     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Keighley MR: Gastrointestinal cancers in Europe. Aliment Pharmacol Ther Suppl 3: 7-30, 2003.
2. Haberland J, Bertz B, Görsch R, Dolle B and Kurth M: Die zukünftige Krebsentwicklung in Deutschland. Bundesgesundheitsbl 49: 459-467, 2006.
3. Starzynska T and Malfertheiner P: Helicobacter and digestive malignancies. Helicobacter 11: 32-35, 2006.
4. Mac Arthur M, Hold GL and El-Omar EM: Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 286: G515-G520, 2004.
5. Suerbaum S and Michetti P: Helicobacter pylori infection. N Engl J Med 347: 1175-1186, 2002.
6. Smith MG, Hold GL, Tahara E and El-Omar EM: Cellular and molecular aspects of gastric cancer. World J Gastroenterol 12: 2979-2990, 2006.
7. Chamaillard M, Girardin SE, Viala V and Philpott DJ: Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation. Cell Microbiol 5: 581-592, 2003.
8. Harton JA, Linhoff MW, Zhang J and Ting JP: Cutting edge: CATERPILLER: a large family of mammalian genes containing CARD, pyrin, nucleotide-binding, and leucine-rich repeat domains. J Immunol 169: 4088-4093, 2002.
9. Bonen DK, Ogura Y, Nicolae DL, Inohara N, Saab L, Tanabe T, Chen FF, Foster SJ, Duerr HR, Brant SR, Cho JH and Nunez G: Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 124: 140-146, 2003.
10. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ and Sansonetti PJ: Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278: 8869-8872, 2003.
11. Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nunez G and Flavell RA: Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307: 731-734, 2005.
12. Lecine P, Esmiol S, Metais JY, Nicoletti C, Nourry C, McDonald C, Nunez G, Hugot JP, Borg JP and Ollendorff V: The NOD2-RICK complex signals from the plasma membrane. J Biol Chem 282: 15197-15207, 2007.
13. Li J, Moran T, Swanson E, Julian C, Harris J, Bonen DK, Hedl M, Nicolae DL, Abraham C and Cho JH: Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet 13: 1715-1725, 2004.
14. Tada H, Aiba S, Shibata K, Ohteki T and Takada H: Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect Immun 73: 7967-7976, 2005.
15. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M and Thomas G: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603, 2001.
16. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G and Cho JH: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 603-606, 2001.
17. Watanabe T, Kitani A and Murray PJ: NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 5: 800-808, 2004.
18. Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, Herrlinger KR, Stallmach A, Noack F, Fritz P, Schroder JM, Bevins CL, Fellermann K and Stange EF: NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 53: 1658-1664, 2004.
19. Viala J, Chaput C, Boneca IG, Cardona A, Girardin SE, Moran AP, Athman R, Mémet S, Huerre MR, Coyle AJ, DiStefano PS, Sansonetti PJ, Labigne A, Bertin J, Philpott DJ and Ferrero RL: Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 5: 1166-1174, 2004.
20. Strober W, Murray PJ, Kitani A and Watanabe T: Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol 6: 9-20, 2006.
21. Rosenstiel P, Hellmig S, Hampe J, Ott S, Till A, Fischbach A, Sahly H, Lucius R, Folsch UR, Philpott D and Schreiber S: Influence of polymorphisms in the NOD1/CARD4 and NOD2/CARD15 genes on the clinical outcome of Helicobacter pylori infection. Cell Microbiol 8: 1188-1198, 2006.
22. Gotze T, Rocken C, Rohl FW, Wex T, Hoffmann J, Westphal S, Malfertheiner P, Ebert MP and Dierkes J: Gene polymorphisms of folate metabolizing enzymes and the risk of gastric cancer. Cancer Lett 251: 228-236, 2007.
23. Laukens D, Peeters H, Marichal D, Vander Cruyssen B, Mielants H, Elewaut D, Demetter P, Cuvelier C, Van Den Berghe M, Rottiers P, Veys EM, Remaut E, Steidler L, De Keyser F and De Vos M: CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease. Ann Rheum Dis 64: 930-935, 2005.
24. Maeda S, Hsu LC, Liu H, Bankston LA, Iimura M, Kagnoff MF, Eckmann L and Karin M: Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 307: 734-738, 2005.
25. Kato I, Canzian F, Plummer M, Franceschi S, van Doorn LJ, Vivas J, Lopez G, Lu Y, Gioia-Patricola L, Severson RK, Schwartz AG and Munoz N: Polymorphisms in genes related to bacterial lipopolysaccharide/peptidoglycan signaling and gastric precancerous lesions in a population at high risk for gastric cancer. Dig Dis Sci 52: 254-261, 2007.
26. Croucher PJ, Mascheretti S, Hampe J, Huse K, Frenzel H, Stoll M, Lu T, Nikolaus S, Yang SK, Krawczak M, Kim HW and Schreiber S: Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur J Hum Genet 11: 6-16, 2003.
27. Schurmann M, Valentonyte R, Hampe J, Muller-Quernheim J, Schwinger E and Schreiber S: CARD15 gene mutations in sarcoidosis. Eur Respir J 22: 748-754, 2003.
28. Buhner S, Buning C, Genschel J, Kling K, Herrmann D, Dignass A, Kuechler I, Krueger S, Schmidt HH and Lochs H: Genetic basis for increased intestinal permeability in families with Crohn's disease: role of CARD15 3020insC mutation? Gut 55: 342-347, 2006.
29. Malfertheiner P, Sipponen P, Naumann M, Moayyedi P, Megraud F, Xiao SD, Sugano K and Nyren O: Lejondal H. pylori-Gastric Cancer Task Force: Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 100: 2100-2115, 2005.
30. Brenner H, Arndt V, Stegmaier C, Ziegler H and Rothenbacher D: Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol 159: 252-258, 2004.